Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of “Moderate Buy” from Brokerages

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $4.80.

KPTI has been the topic of a number of research analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. StockNews.com upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Robert W. Baird cut their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th.

Institutional Trading of Karyopharm Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of KPTI. BNP Paribas Financial Markets boosted its position in shares of Karyopharm Therapeutics by 6.5% during the fourth quarter. BNP Paribas Financial Markets now owns 1,769,184 shares of the company’s stock valued at $1,530,000 after buying an additional 108,286 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Karyopharm Therapeutics by 494.5% during the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock worth $649,000 after acquiring an additional 622,194 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth $494,000. Ikarian Capital LLC raised its holdings in shares of Karyopharm Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock valued at $618,000 after purchasing an additional 9,355 shares during the last quarter. Finally, Panagora Asset Management Inc. bought a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at about $197,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Stock Performance

Shares of KPTI opened at $0.74 on Tuesday. The firm has a market cap of $91.97 million, a PE ratio of -0.58 and a beta of 0.20. Karyopharm Therapeutics has a 52-week low of $0.62 and a 52-week high of $1.95. The business’s 50 day moving average price is $0.84 and its two-hundred day moving average price is $1.03.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The company had revenue of $42.79 million for the quarter, compared to analyst estimates of $36.07 million. Research analysts predict that Karyopharm Therapeutics will post -0.93 EPS for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).